153 related articles for article (PubMed ID: 18563366)
1. Pharmacokinetic/pharmacodynamic modeling of the cardiovascular effects of beta blockers in humans.
Baek IH; Yun MH; Yun HY; Kwon KI
Arch Pharm Res; 2008 Jun; 31(6):814-21. PubMed ID: 18563366
[TBL] [Abstract][Full Text] [Related]
2. Comparison of different pharmacodynamic models for pharmacokinetic-pharmacodynamic (PK-PD) modeling of carvedilol.
Liu XY; Wang BJ; Yuan GY; Guo RC
Yao Xue Xue Bao; 2009 Apr; 44(4):406-11. PubMed ID: 19545060
[TBL] [Abstract][Full Text] [Related]
3. Is urethane-chloralose anaesthesia appropriate for pharmacokinetic-pharmacodynamic assessment? Studies with carvedilol.
Bertera FM; Di Verniero CA; Mayer MA; Bramuglia GF; Taira CA; Höcht C
J Pharmacol Toxicol Methods; 2009; 59(1):13-20. PubMed ID: 18973819
[TBL] [Abstract][Full Text] [Related]
4. Unpredicted lack of effect of exercise on plasma concentrations of carvedilol.
Stoschitzky K; Zweiker R; Klein W; Zitta S; Gruber L; Lamprecht G; Lindner W
J Cardiovasc Pharmacol; 2002 Jan; 39(1):58-60. PubMed ID: 11743228
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic drug-drug interaction assessment between LCZ696, an angiotensin receptor neprilysin inhibitor, and hydrochlorothiazide, amlodipine, or carvedilol.
Hsiao HL; Langenickel TH; Greeley M; Roberts J; Zhou W; Pal P; Rebello S; Rajman I; Sunkara G
Clin Pharmacol Drug Dev; 2015 Nov; 4(6):407-17. PubMed ID: 27137712
[TBL] [Abstract][Full Text] [Related]
6. Estimation of carvedilol in human plasma by using HPLC-fluorescence detector and its application to pharmacokinetic study.
Rathod R; Prasad LP; Rani S; Nivsarkar M; Padh H
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Oct; 857(2):219-23. PubMed ID: 17702675
[TBL] [Abstract][Full Text] [Related]
7. Development of a pharmacokinetic/pharmacodynamic model for carvedilol to predict beta1-blockade in patients with congestive heart failure.
Tenero DM; Henderson LS; Campanile AM; Baidoo CA; Boyle D
Am J Cardiol; 2006 Oct; 98(7A):27L-31L. PubMed ID: 17023229
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of carvedilol after intravenous and oral administration in conscious healthy dogs.
Arsenault WG; Boothe DM; Gordon SG; Miller MW; Chalkley JR; Petrikovics I
Am J Vet Res; 2005 Dec; 66(12):2172-6. PubMed ID: 16379664
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension.
Henderson LS; Tenero DM; Baidoo CA; Campanile AM; Harter AH; Boyle D; Danoff TM
Am J Cardiol; 2006 Oct; 98(7A):17L-26L. PubMed ID: 17023228
[TBL] [Abstract][Full Text] [Related]
10. PK-PD modeling of irbesartan in healthy Chinese adult volunteers under non-steady-state conditions.
Huang XH; Li J; Qiu FR; Xie HT; Huang JH; Li JC; Zheng QS
Eur J Drug Metab Pharmacokinet; 2006; 31(4):259-64. PubMed ID: 17315536
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic properties of a new controlled-release formulation of carvedilol.
Tenero DM; Henderson LS; Baidoo CA; Harter AH; Campanile AM; Danoff TM; Boyle D
Am J Cardiol; 2006 Oct; 98(7A):5L-16L. PubMed ID: 17023227
[TBL] [Abstract][Full Text] [Related]
12. The impact of paroxetine coadministration on stereospecific carvedilol pharmacokinetics.
Stout SM; Nielsen J; Bleske BE; Shea M; Brook R; Kerber K; Welage LS
J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):373-9. PubMed ID: 20705902
[TBL] [Abstract][Full Text] [Related]
13. β-blockers: a review of their pharmacological and physiological diversity in hypertension.
Ripley TL; Saseen JJ
Ann Pharmacother; 2014 Jun; 48(6):723-33. PubMed ID: 24687542
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the pharmacokinetic properties of bisoprolol and carvedilol in healthy dogs.
Beddies G; Fox PR; Papich MD; Kanikanti VR; Krebber R; Keene BW
Am J Vet Res; 2008 Dec; 69(12):1659-63. PubMed ID: 19046015
[TBL] [Abstract][Full Text] [Related]
15. Preparation and evaluation of SEDDS and SMEDDS containing carvedilol.
Wei L; Sun P; Nie S; Pan W
Drug Dev Ind Pharm; 2005 Sep; 31(8):785-94. PubMed ID: 16221613
[TBL] [Abstract][Full Text] [Related]
16. Exercise does not affect plasma concentrations of (R)- and (S)-carvedilol.
Stoschitzky K; Koshucharova G; Zweiker R; Lercher P; Maier R; Klein W; Zitta S; Gruber L; Lamprecht G; Lindner W
Cardiovasc Drugs Ther; 2002 Mar; 16(2):133-40. PubMed ID: 12090906
[TBL] [Abstract][Full Text] [Related]
17. Effect of dronedarone on the pharmacokinetics of carvedilol following oral administration to rats.
Kim MS; Baek IH
Eur J Pharm Sci; 2018 Jan; 111():13-19. PubMed ID: 28942006
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic properties of carvedilol in fructose hypertensive rats.
Bertera F; Di Verniero CA; Mayer MA; Chiappetta D; Buontempo F; Polizio AH; Taira CA; Höcht C
Xenobiotica; 2012 Feb; 42(2):206-19. PubMed ID: 21892881
[TBL] [Abstract][Full Text] [Related]
19. Carvedilol and atenolol once daily in the treatment of hypertension.
Luurila OJ; Härkönen R; Hilden M; Icen R; Kohvakka A; Linna M; Sillanpää J; Vänskä O; Lukkala K
J Hypertens Suppl; 1989 Dec; 7(6):S264-5. PubMed ID: 2576666
[TBL] [Abstract][Full Text] [Related]
20. Analysis of carvedilol enantiomers in human plasma using chiral stationary phase column and liquid chromatography with tandem mass spectrometry.
Poggi JC; Da Silva FG; Coelho EB; Marques MP; Bertucci C; Lanchote VL
Chirality; 2012 Mar; 24(3):209-14. PubMed ID: 22271587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
